Advances in the Classification and Management of Patients With T-Cell Lymphoma

H&O What are the most common types of T-cell lymphoma? LP T-cell lymphoma is a heterogeneous group of disorders that encompass many subtypes. T-cell lymphomas that […]

Hyper-CVAD–Based Regimens in Adult Patients With Acute Lymphoblastic Leukemia

H&O How was the hyper-CVAD regimen originally used? EJ The hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD) regimen was developed by Kantarjian and colleagues at MD […]

The Future Role of Bispecific Antibodies in Lymphoma

H&O What is the mechanism of action of bispecific antibodies? JA Bispecific antibodies aim to harness the power of the immune system. These treatments are monoclonal […]

New Approaches to T-Cell Acute Lymphoblastic Leukemia

H&O How common is T-cell acute lymphoblastic leukemia (T-ALL)? DT ALL is uncommon, accounting for approximately 6700 new diagnoses per year in the United States. Between […]

Insights Into the Management of Patients With Primary Central Nervous System Lymphoma

H&O What is the definition of primary central nervous system (CNS) lymphoma ? CF Primary CNS lymphoma is referred to as primary diffuse large B-cell lymphoma […]

Evolving Management of Patients With Double-Hit Lymphoma

H&O What is the definition of double-hit lymphoma? AL Double-hit lymphoma is an aggressive B-cell lymphoma with MYC translocation and a BCL2 and/or BCL6 translocation. The […]

Recent Data for Acalabrutinib in Chronic Lymphocytic Leukemia

H&O What type of drug is acalabrutinib? PG Acalabrutinib (Calquence, AstraZeneca) is a so-called next-generation Bruton’s tyrosine kinase (BTK) inhibitor. The first-generation BTK inhibitor, ibrutinib (Imbruvica, […]

Umbralisib and Ublituximab: An Upcoming Regimen for Chronic Lymphocytic Leukemia

H&O What types of drugs are umbralisib and ublituximab? JG Umbralisib (Ukoniq, TG Therapeutics) is a phosphoinositide 3 (PI3) kinase delta inhibitor. Umbralisib is approved for […]

Zanubrutinib: A Novel BTK Inhibitor in Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma

H&O What type of drug is zanubrutinib? CT Zanubrutinib, also known as BGB-3111, is a next-generation Bruton’s tyrosine kinase (BTK) inhibitor. It inhibits BTK irreversibly […]

Guideline Recommendations for the Prophylaxis of Invasive Aspergillosis in AML

Clinical Advances in Hematology & Oncology Volume 14, Issue 11, November 2016 Eunice S. Wang, MD Chief, Leukemia Service Professor of Oncology, Department of Medicine Roswell […]

Consolidation Therapy After Autologous Stem Cell Transplant in Relapsed/Refractory Hodgkin Lymphoma

Clinical Advances in Hematology & Oncology Volume 14, Issue 9, September 2016 Craig H. Moskowitz, MD Steven A. Greenberg Chair in Lymphoma Research Clinical Director, Division […]

Are We Ready for Precision Medicine in Acute Myeloid Leukemia?

Clinical Advances in Hematology & Oncology Volume 14, Issue 8, August 2016 Advances in LLM Gail J. Roboz, MD Professor of Medicine Weill Cornell Medicine […]

Management of Invasive Aspergillosis in Acute Myelogenous Leukemia

Clinical Advances in Hematology & Oncology Volume 14, Issue 7, July 2016 Bruno C. Medeiros, MD Associate Professor of Medicine (Hematology) Stanford University School of Medicine […]

Personalized Treatment for Patients With Myelofibrosis

Clinical Advances in Hematology & Oncology Volume 14, Issue 6, June 2016 Tapan M. Kadia, MD Associate Professor The University of Texas MD Anderson Cancer Center […]

Preventive Strategies for Invasive Aspergillus in Acute Myelogenous Leukemia

Clinical Advances in Hematology & Oncology Volume 14, Issue 5, May 2016 Gary Schiller, MD Professor of Medicine Division of Hematology/Oncology David Geffen School of Medicine […]

Blastic Plasmacytoid Dendritic Cell Neoplasm

Clinical Advances in Hematology & Oncology April 2016, Volume 14, Issue 4 Naveen Pemmaraju, MD Assistant Professor Department of Leukemia Division of Cancer Medicine The University […]

The Use of Ibrutinib in Chronic Lymphocytic Leukemia

Clinical Advances in Hematology & Oncology March 2016, Volume 14, Issue 3 Lloyd E. Damon, MD Clinical Professor, Department of Medicine Director, Hematologic Malignancies and Bone […]

Are Chimeric Antigen Receptor T Cells Ready for Prime Time?

Clinical Advances in Hematology & Oncology January 2016, Volume 14, Issue 1 Renier J. Brentjens, MD, PhD Director, Cellular Therapeutics Memorial Sloan Kettering Cancer Center […]

Use of PCR Testing in Chronic Myeloid Leukemia

Clinical Advances in Hematology & Oncology December 2015, Volume 13, Issue 12 Elias J. Jabbour, MD Associate Professor Department of Leukemia The University of Texas MD […]

Current Treatment Approaches in Follicular Lymphoma

Clinical Advances in Hematology & Oncology November 2015, Volume 13, Issue 11 Brad S. Kahl, MD Professor of Medicine Washington University School of Medicine St Louis, […]